Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers

Zacny, James P.; Gutierrez, Sandra

doi:10.1007/s00213-011-2349-6

Cited by 44 publications

(31 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were two different time points in the session when capsules were given because in the session when we tested the effects of 75 mg pregabalin in combination with 10 mg oxycodone, we wanted to measure their effects when the drugs were both close to, or at, their peak effects. In a preliminary pilot study we noted that the psychoactive effects of pregabalin tended to peak two hours after its administration, and prior studies with 10 mg oxycodone conducted in our laboratory indicated peak effects one hour after its administration (Zacny and Gutierrez, 2011; Zacny and Lichtor, 2008). …”

Section: Methodsmentioning

confidence: 77%

Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers

Zacny

Paice

Coalson

2012

Pharmacology Biochemistry and Behavior

Self Cite

View full text Add to dashboard Cite

Pregabalin is an anticonvulsant drug indicated for neuropathic disorders and fibromyalgia. Some chronic pain patients suffering from these disorders take both this drug and an opioid for pain relief. Pregabalin is a scheduled drug under the Controlled Substance Act. The subjective effects of this drug have not been well-characterized, and the extent to which it alters the subjective effects of opioids has not been studied to the best of our knowledge. Using a double-blind, randomized, crossover design, 16 healthy volunteers were administered (in separate sessions) capsules containing placebo, 75 mg pregabalin, 150 mg pregabalin, 10 mg oxycodone, and 75 mg pregabalin combined with 10 mg oxycodone. Subjective, psychomotor, and physiological measures were assessed during each of the five sessions. Pregabalin produced dose-related increases in some subjective effects and decreased respiration rate, but did not impact on psychomotor performance. Abuse liability-related subjective effects such as drug liking and desire to take the drug again were not increased by either pregabalin dose. Oxycodone produced increases in several subjective effects, including ratings of drug liking. When 75 mg pregabalin was combined with oxycodone some subjective effects were altered relative to placebo, in contrast to when each drug was tested alone. Liking of oxycodone was not increased by 75 mg pregabalin. However, recent studies have suggested that this drug is abused, and we would recommend that further psychopharmacological studies with pregabalin are warranted, including a study assessing its abuse liability across a range of doses in sedative abusers.

show abstract

Section: Methodsmentioning

confidence: 77%

Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers

Zacny

Paice

Coalson

2012

Pharmacology Biochemistry and Behavior

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, mixing prescription stimulants and alcohol can override the protective mechanism of passing out when drinking and approaching dangerous blood-alcohol concentrations which can lead to life-threatening consequences (SAMHSA, 2006). In addition, there is evidence that alcohol increases the subjective effects (e.g., drug liking and euphoria) of prescription opioids, which may partially explain why alcohol and prescription opioids are often simultaneously co-ingested (Zacny and Gutierrez, 2011). Notably, central nervous system depressants (e.g., prescription opioids, sedatives and tranquilizers) are much more toxic and associated with more severe consequences when they are taken with other drugs that depress the central nervous system, such as alcohol, as compared to when they are taken alone (Cone et al, 2004; McCabe et al, 2006; SAMHSA, 2014).…”

Section: 0 Discussionmentioning

confidence: 99%

High-intensity drinking and nonmedical use of prescription drugs: Results from a national survey of 12th grade students

McCabe

Veliz

Patrick

2017

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background Nearly 10% of U.S. 12th graders report high-intensity drinking (10+ or 15+ drinks in a row), but the extent to which these drinkers also engage in nonmedical use of prescription drugs (NMUPD) is largely unknown. This study examined the associations between different thresholds of past two-week high-intensity drinking and past-month NMUPD among U.S. 12th graders. Methods The sample consisted of eleven nationally representative cross-sections of 12th graders in the Monitoring the Future study (2005–2015) who answered questions on past two-week drinking behaviors and past-month nonmedical use of prescription opioids, sedative, stimulants, and tranquilizers (N = 26,502 respondents). Results High-intensity drinking during the past two-weeks was associated with an increased risk of past-month NMUPD. The odds of NMUPD were four times larger among 12th graders who indicated drinking 15 or more drinks on at least one occasion (AOR = 4.43, 95% CI = 3.18, 5.01) relative to those who had 0 to 4 drinks during the past two-weeks, after adjusting for relevant covariates. These associations were similar across different classes of prescription drugs and tended to be stronger among non-white respondents. A sub-analysis revealed simultaneous co-ingestion of alcohol and NMUPD was more prevalent among high-intensity drinkers. Conclusions More than 1 in every 4 U.S 12th graders who engage in high-intensity drinking (15+ drinks in a row) also report NMUPD. Given the greater likelihood of simultaneous co-ingestion of alcohol and prescription drugs among high-intensity drinkers, adolescent substance use interventions need to address the risks associated with mixing alcohol and prescription drugs.

show abstract

“…Increases in positive subjective effects (eg, “drug liking,” “take again,” “pleasant body sensations”) have been reported by healthy volunteers administered a combination of oxycodone (10 mg) and ethanol (0.3 or 0.6 g/kg) compared with when they received either substance alone (Figure 5). 47 Psychomotor and cognitive performances were not affected by any of the active drug scenarios.…”

Section: Prevalence and Risk Factorsmentioning

confidence: 92%

Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use

Gudin

Mogali

Jones

et al. 2013

Postgraduate Medicine

199

122

View full text Add to dashboard Cite

The concurrent use of opioids, benzodiazepines (BZDs), and/or alcohol poses a formidable challenge for clinicians who manage chronic pain. While the escalating use of opioid analgesics for the treatment of chronic pain and the concomitant rise in opioid-related abuse and misuse are widely recognized trends, the contribution of combination use of BZDs, alcohol, and/or other sedative agents to opioid-related morbidity and mortality is underappreciated, even when these agents are used appropriately. Patients with chronic pain who use opioid analgesics along with BZDs and/or alcohol are at higher risk for fatal/nonfatal overdose and have more aberrant behaviors. Few practice guidelines for BZD treatment are readily available, especially when they are combined clinically with opioid analgesics and other central nervous system–depressant agents. However, coadministration of these agents produces a defined increase in rates of adverse events, overdose, and death, warranting close monitoring and consideration when treating patients with pain. To improve patient outcomes, ongoing screening for aberrant behavior, monitoring of treatment compliance, documentation of medical necessity, and the adjustment of treatment to clinical changes are essential. In this article, we review the prevalence and pharmacologic consequences of BZDs and/or alcohol use among patients with pain on chronic opioid therapy, as well as the importance of urine drug testing, an indispensable tool for therapeutic drug monitoring, which helps to ensure the continued safety of patients. Regardless of risk or known aberrant drug-related behaviors, patients on chronic opioid therapy should periodically undergo urine drug testing to confirm adherence to the treatment plan.

show abstract

Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers

Cited by 44 publications

References 43 publications

Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers

Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers

High-intensity drinking and nonmedical use of prescription drugs: Results from a national survey of 12th grade students

Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use

Contact Info

Product

Resources

About